The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines

PharmacoEconomics

Volumn 14, Issue SUPPL. 3, 1998, Pages 19-28

  McKenney, James M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

EID: 0032419989     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814003-00003     Document Type: Review

References (57)

1. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas: American Heart Association, 1997
2. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 Suppl.: S1-9
3. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997; 79: 756-62
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvaslatin Survival Study (4S). Lancet 1994; 344: 1383-9
5. Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
8. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
11. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
12. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52
13. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and the European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
14. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445
15. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47
16. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA task force on risk reduction. Circulation 1998; 97: 1876-87
17. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprolein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82: 61-5
18. Schwartz JS, Boccuzzi SJ, Murray JF, et al. Cost effectiveness of LDL-C reduction in Medicare managed care CHD patients: implications from the Scandinavian Simvastatin Survival Study (4S) [abstract no. 767-2]. J Am Coll Cardiol 1997; 29 Suppl. A: 226
19. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75 (17): 1196-201
20. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306: 1367-73
21. Magnani HN. The hypolipidaemic drug market. Scrip's 1991 hypolipidaemic report. Scrip 1992
22. Grundy SM. Cholesterol and coronary heart disease. The 21st century. Arch Intern Med 1997; 157 (11): 1177-84
23. National Heart, Lung, and Blood Institute. National Heart, Lung, and Blood Institute cholesterol awareness surveys, 1995. Presented at a press conference of the National Heart, Lung, and Blood Institute: December 4, 1995; Bethesda, Maryland
24. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996; 75: 334-42
25. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100 (6): 605-10
26. Pearson TA, Laurora IM. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP) [abstract Mrael no. 361]. Circulation 1997; 96 Suppl. 1: 1-66
27. Shepherd J, Cob SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
28. Simes RJ, Baker S, MacMahon S, et al. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID trial. Presented at the 47th Annual Scientific Session of the American College of Cardiology; 1998 Mar 29-Apr 1; Atlanta, Georgia, USA
29. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19 (9): 683-9
30. Goldman L, Garber AM, Grover SA, et al. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27: 964-1047
31. Reckless JPD. Cost implications of lipid-lowering treatments. Pharmacoeconomics 1994; 6: 310-23
32. Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997; 2: 231-50
33. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 95: 1796-802
34. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease [comments]. Am J Cardiol 1996; 78 (4): 409-14
35. Furberg CD, Pitt B, Byington RP, et al. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Am J Cardiol 1995; 76 (9): 60C-3C
36. Elliot WJ, Weir DR. Comparalive cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of myocardial infarction [abstract no. LC-15]. Association of Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference; 1997 Nov 5-7; Orlando, Florida
37. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group [comments]. N Engl J Med 1997; 336 (5): 332-6
38. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) [comments]. Eur Heart J 1996; 17 (7): 1001-7
39. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90
40. Williams A. Economics of coronary artery bypass grafting. BMJ 1985; 291: 326-9
41. Wong JB, Sonnenberg FA, Salem DN, et al. Myocardial revascularization for chronic stable angina. Ann Intern Med 1990; 113: 852-7
42. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation 1982; 66 Suppl. 3: 11156-66
43. Goldman L, Sia STB, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319: 152-7
44. Wilhelmsson C, Vedin A, Wilhelmsson L. Cost-benefit aspects of post-myocardial infarction interventions. Acta Med Scand 1981; 651: 317-20
45. Olssun G, Levin L-A, Rehnqvist N. Economic consequences of postinfarction prophylaxis with β blockers: cost effectiveness of metoprolol. BMJ 1987; 294: 339-42
46. Hay JW, Yuan Y, Ford I, et al. Pravastatin cost-effectiveness for primary prevention of cardiovascular disease in the US [abstract 1017]. 70th Scientific Sessions of the American Heart Association: 1997 Nov 10-13; Orlando, Florida
47. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-8
48. Haq IU, Ramsay LE, Pickin DM, et al. Lipid lowering for prevention of coronary heart disease: what policy now? Clin Sci (Colch) 1996; 91: 399-413
49. Johannesson M, Borgquist L,. Jönsson B, et al. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 1996; 240: 23-9
50. Husc DM, Russell MW, Kraemer DF. et al. Cost-effectiveness of HMG-CoA-reductase inhibition in primary prevention of CHD: new evidence comparing all available agents [abstract no. LC-21 (poster)]. Association of Pharmacocconomics and Outcomes Research: The APOR I Lipid Conference; 1997 Nov 5-7; Orlando, Florida
51. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovasiatin, and flusvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-7
52. Caro J, Klittich W, McGuirc A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82
53. Working Group on Acute Purchasing. Statin therapy/HMG-CoA rcductase inhibitor treatment in the prevention of coronary heart disease. Sheffield: Trent Institute for Health Services Research, University of Sheffield, 1996
54. Wakeman AP, Leach RH. Health authorities must work with clinicians to target statins [letter]. BMJ 1997; 315: 1618
55. Hilleman DE, Mohiuddin SM, Wurdenian RL, et al. The CURVES trial: a pharmacoeconomic evaluation [abstract no. LD-19 (poster)). Association of Pharmacoeconomics and Outcomes Research: The APOR Lipid Conference; 1997 Nov 5-7; Orlando, Florida
56. Koren MJ, Smith DG, Himninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin. lovastalin and fluvasiatin. Pharmacoeconomics 1998: 14:59-70
57. Monarty PM Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results. Am J Cardiol 1998: 82: 505-7